Building Immune Organoids From Children's Cancer Tissue
Lab-grown immune models made from tumor and skin samples of children with cancer.
Key facts
- Who runs it
- Gustave Roussy, Cancer Campus, Grand Paris
- Where
- Paris and Villejuif, FranceSee the 2 sites
- Trial code
- Registry title
- Engineering Immune Organoids to Study Pediatric Cancer
- Status
- Recruiting
- People taking part
- 108 people, planned
- Started
- 12 May 2023
- Expected to end
- May 2028
- Type of study
- Interventional
- Treatments tested
- Skin biopsy
- Fresh tumor sample
- Blood sample
- Healthy tissue from the tumor
- Spinal cerebrospinal fluid (SCF)
- Record updated
- 9 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people with a brain tumor, kidney tumor, neuroblastoma or sarcoma. Samples from their tissues will be used to grow immune organoids.
- Age
- Up to 25 years at diagnosis. No upper age limit for malignant gliomas and kidney (renal) tumors.
- Sex
- All sexes can join.
- Disease stage
- Suspected or confirmed brain tumors, renal tumors, neuroblastoma or sarcomas, at any stage.
Main reasons for not taking part
- Any tumor type not named in the inclusion criteria
- Patient or parents/guardians unable to give consent
- Patients deprived of their liberty by a judicial or administrative decision
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied
- Medical suspicion or diagnosis of one of the following diseases, regardless of stage:
- Brain tumors
- Renal tumors
- Neuroblastoma
- Sarcomas
- Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol
- Affiliated to a social security system or beneficiary of the same
Who cannot take part
- Any histology not mentioned in the inclusion criteria
- Adult patient or parents/guardians incapable/incapable of giving its/their consent
- Patients deprived of their liberty by a judicial or administrative decision
Where in France
- Hôpital NeckerParis, FranceContact: Kevin BECCARIATaking people
- Gustave RoussyVillejuif, FranceContact: Claudia PASQUALINITaking people
About the trial
What the trial wants to find out
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
The group in the trial
- Immune organoids from pediatric patient tissues using iPSCOther group
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
Treatment: Skin biopsy, Fresh tumor sample, Blood sample, Healthy tissue from the tumor, and Spinal cerebrospinal fluid (SCF)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)
- Plain-language title
- Building Immune Organoids From Children's Cancer TissueGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 February 2026